DE69636216D1 - Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen - Google Patents

Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen

Info

Publication number
DE69636216D1
DE69636216D1 DE69636216T DE69636216T DE69636216D1 DE 69636216 D1 DE69636216 D1 DE 69636216D1 DE 69636216 T DE69636216 T DE 69636216T DE 69636216 T DE69636216 T DE 69636216T DE 69636216 D1 DE69636216 D1 DE 69636216D1
Authority
DE
Germany
Prior art keywords
cell
identified
genes
immune
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636216T
Other languages
English (en)
Other versions
DE69636216T2 (de
Inventor
A Levinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69636216D1 publication Critical patent/DE69636216D1/de
Publication of DE69636216T2 publication Critical patent/DE69636216T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60G—VEHICLE SUSPENSION ARRANGEMENTS
    • B60G13/00—Resilient suspensions characterised by arrangement, location or type of vibration dampers
    • B60G13/001—Arrangements for attachment of dampers
    • B60G13/003—Arrangements for attachment of dampers characterised by the mounting on the vehicle body or chassis of the damper unit
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/30—Animal model comprising expression system for selective cell killing, e.g. toxins, enzyme dependent prodrug therapy using ganciclovir
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
DE69636216T 1995-03-03 1996-03-01 Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen Expired - Lifetime DE69636216T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US398633 1995-03-03
US08/398,633 US6066322A (en) 1995-03-03 1995-03-03 Methods for the treatment of immune disorders
US487748 1995-06-07
US08/487,748 US5721351A (en) 1995-03-03 1995-06-07 Compositions and methods for the treatment and diagnosis of immune disorders
PCT/US1996/002798 WO1996027603A1 (en) 1995-03-03 1996-03-01 Compositions and methods for the treatment and diagnosis of immune disorders

Publications (2)

Publication Number Publication Date
DE69636216D1 true DE69636216D1 (de) 2006-07-20
DE69636216T2 DE69636216T2 (de) 2007-04-19

Family

ID=27016314

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636216T Expired - Lifetime DE69636216T2 (de) 1995-03-03 1996-03-01 Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen

Country Status (9)

Country Link
US (10) US6066322A (de)
EP (2) EP0813538B1 (de)
JP (1) JPH11501807A (de)
AT (1) ATE328891T1 (de)
AU (1) AU718245B2 (de)
CA (1) CA2214589A1 (de)
DE (1) DE69636216T2 (de)
ES (1) ES2264800T3 (de)
WO (1) WO1996027603A1 (de)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479269B2 (en) * 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US20030069196A1 (en) * 1995-03-03 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US5633161A (en) 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US20020106741A1 (en) * 1995-06-06 2002-08-08 Human Genome Sciences, Inc. G protein receptor HTNAD29
EP0832126A4 (de) * 1995-06-06 2000-01-12 Human Genome Sciences Inc G-protein rezeptor htnad29
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
EE04817B1 (et) * 1996-05-24 2007-04-16 Biogen, Incorporated Kudede regeneratsiooni modulaatorid
WO1997046677A1 (fr) * 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
US20030170864A1 (en) 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1346999A3 (de) * 1997-07-16 2003-10-01 Human Genome Sciences Humane sekretierte Proteine
WO1999010536A1 (en) * 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
US7160985B2 (en) * 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
ZA989497B (en) * 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
US7193057B2 (en) * 1997-10-29 2007-03-20 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in rectal tumor
JPH11190734A (ja) * 1997-12-26 1999-07-13 Wakamoto Pharmaceut Co Ltd クローン病の検査方法および検査用キット
WO1999033479A1 (en) * 1997-12-31 1999-07-08 University Of Iowa Research Foundation Use of parasitic biological agents for prevention and control of autoimmune diseases
US20050202458A1 (en) * 1998-03-31 2005-09-15 Roberts Bruce L. Antigen-specific cells, methods of generating these cells and uses thereof
WO1999057130A1 (en) * 1998-05-05 1999-11-11 Gene Logic, Inc. A process to study changes in gene expression in t lymphocytes
US7351543B2 (en) * 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US20030105298A1 (en) 1998-06-16 2003-06-05 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7319008B2 (en) * 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
US20030109681A1 (en) * 1998-06-10 2003-06-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US7244428B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7244817B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
CA2343006A1 (en) * 1998-09-17 2000-03-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7399828B2 (en) * 1998-09-24 2008-07-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
US7402661B2 (en) * 1998-10-06 2008-07-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
US20070072248A1 (en) * 1998-10-13 2007-03-29 Arena Pharmaceuticals, Inc. Constitutively activated human G protein coupled receptors
US7507404B2 (en) * 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20010103046A (ko) * 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
AU782985B2 (en) * 1999-04-09 2005-09-15 Curagen Corporation Novel human proteins and polynucleotides encoding them
US20080286821A1 (en) * 1999-05-14 2008-11-20 Eaton Dan L Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000073498A1 (en) * 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
DE60035693T2 (de) * 1999-07-20 2008-05-15 Genentech, Inc., South San Francisco Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
AU7079300A (en) * 1999-08-31 2001-03-26 Genentech Inc. Compositions and methods for the treatment of immune related diseases
AU3902600A (en) * 1999-09-15 2001-04-17 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
JP4211966B2 (ja) * 1999-11-30 2009-01-21 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物及び方法
US7300758B2 (en) * 1999-12-09 2007-11-27 Genetech, Inc. Nucleic acid underexpressed in esophageal tumor
US20060160186A1 (en) * 1999-12-09 2006-07-20 Eaton Dan L Nucleic acid underexpressed in stomach tumor and lung tumor
US7423127B2 (en) 1999-12-09 2008-09-09 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
US7288384B2 (en) * 1999-12-09 2007-10-30 Genentech, Inc. Antibodies to polypeptides encoded by a nucleic acid underexpressed in esophageal tumor
JP3460673B2 (ja) * 2000-02-04 2003-10-27 浜松ホトニクス株式会社 特定の遺伝子を発現した生細胞の選択的分離方法
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US7135278B1 (en) * 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
WO2002027027A2 (en) * 2000-09-29 2002-04-04 University Of Rochester Method of screening for therapeutics for infectious diseases
AU2001290316A1 (en) * 2000-10-02 2002-04-15 Mochida Pharmaceutical Co., Ltd. Gata-3 expression inhibitor and method of screening the same
ZA200303132B (en) * 2000-10-20 2004-09-23 Expression Diagnostics Inc Leukocyte expression profiling.
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
JPWO2002066979A1 (ja) * 2001-02-22 2004-06-24 タカラバイオ株式会社 気管支喘息原因抗原の検出方法
WO2002087424A2 (en) 2001-05-02 2002-11-07 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
WO2003002722A2 (en) * 2001-06-29 2003-01-09 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes and methods of use thereof
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
US7068603B2 (en) * 2001-07-06 2006-06-27 Juniper Networks, Inc. Cross-bar switch
JP2003076656A (ja) * 2001-09-05 2003-03-14 Sony Corp 情報処理システム、情報処理装置および方法、記録媒体、並びにプログラム
WO2003023056A2 (en) * 2001-09-12 2003-03-20 F. Hoffmann-La Roche Ag Specific markers for multiple sclerosis
US7202335B2 (en) * 2001-12-06 2007-04-10 Genentech, Inc. PRO300 polypeptides
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2013200694B2 (en) * 2002-01-30 2016-03-17 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US8043603B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
JP3828443B2 (ja) * 2002-03-22 2006-10-04 株式会社東芝 赤外線撮像装置及びその製造方法
ES2685697T3 (es) * 2002-05-09 2018-10-10 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
JP4689275B2 (ja) * 2002-12-30 2011-05-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１アンタゴニストおよび免疫系を調節するための使用
WO2004083366A2 (en) * 2003-03-17 2004-09-30 Riikka Lund Methods utilizing novel target genes related to immune-mediated diseases
WO2004084822A2 (en) * 2003-03-21 2004-10-07 The Regents Of Iniversity Of California Methods for inducing immune tolerance
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20070248978A1 (en) * 2006-04-07 2007-10-25 Expression Diagnostics, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
WO2004110250A2 (en) * 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20060216716A1 (en) * 2003-08-14 2006-09-28 Saubermann Lawrence J Immunologic activity measures for t helper on-associated conditions
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
RU2006114694A (ru) 2003-10-03 2007-11-10 Брихэм Энд Уимен`З Хоспитал (Us) Tim-3-полипептиды
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
EA200601761A1 (ru) * 2004-03-24 2007-06-29 Телос Фармасьютикалз, Инк. Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
DE112005001901T5 (de) * 2004-08-04 2007-07-12 Aspira Biosystems Inc., Incline Village Einfangen und entfernen von Biomolekülen aus Körperflüssigkeiten unter Verwendung von partiellen molekularen Abdrücken
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
FI20041204A0 (fi) * 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
ES2731448T3 (es) * 2004-12-23 2019-11-15 Purdue Research Foundation Procedimiento de análisis por imagen mediante tomografía por emisión de positrones
US8206705B2 (en) * 2005-03-02 2012-06-26 Biogen Idec Ma Inc. KIM-1 antibodies for treatment of TH2-mediated conditions
EP1885889A4 (de) * 2005-05-11 2010-01-20 Expression Diagnostics Inc Verfahren zur überwachung des betriebsstatus von transplantaten über genlisten
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
WO2007022625A1 (en) * 2005-08-22 2007-03-01 Caprion Pharmaceuticals Inc. Peptide reversion methods and uses thereof
EP1940473A2 (de) 2005-09-23 2008-07-09 Purdue Research Foundation Verfahren und vorrichtung für die multiphotonen-in-vivo-durchflusszytometrie
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
US20090305265A1 (en) * 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
HUE028594T2 (en) * 2006-05-01 2016-12-28 Critical Care Diagnostics Inc Diagnosis of cardiovascular disease
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
ES2385754T3 (es) * 2006-06-22 2012-07-31 Novo Nordisk A/S Receptores heterodiméricos solubles y usos de estos
WO2008021431A2 (en) * 2006-08-14 2008-02-21 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
WO2008140484A2 (en) * 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2567711A3 (de) 2007-02-07 2013-05-01 Purdue Research Foundation Bildgebungsverfahren für Positronenemissionstomographie
WO2008101354A1 (en) * 2007-02-22 2008-08-28 Merck Frosst Canada Ltd Gpr65 as a therapeutic target in allergic airway inflammation
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
WO2009081854A1 (ja) * 2007-12-21 2009-07-02 University Of Toyama アレルギー性疾患のバイオマーカーおよびその利用
ES2687401T3 (es) 2008-04-18 2018-10-25 Critical Care Diagnostics, Inc. Predicción del riesgo a sufrir episodios cardíacos adversos graves
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
EP2272977A1 (de) * 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnoseverfahren und Satz zur Detektion einer lymphozytären Variante des hypereosinophilen Syndroms
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
CN104619839A (zh) 2012-08-03 2015-05-13 西塞医疗中心 药物递送蛋白质的增强运输的突变体的分离
JP6450679B2 (ja) 2012-08-21 2019-01-09 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3191127A1 (de) 2014-09-13 2017-07-19 Novartis AG Kombinationstherapien von egfr-inhibitoren
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2016293667A1 (en) 2015-07-14 2018-01-04 Kyowa Kirin Co., Ltd. A therapeutic agent for a tumor comprising an IDO inhibitor administered in combination with an antibody
ES2886569T3 (es) 2015-10-02 2021-12-20 Hoffmann La Roche Anticuerpos biespecíficos específicos para PD1 y TIM3
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US10077306B2 (en) 2016-07-14 2018-09-18 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
EP3367098A1 (de) * 2017-02-24 2018-08-29 CeMM - Forschungszentrum für Molekulare Medizin GmbH Verfahren zur bestimmung der interaktion zwischen biologischen zellen
RU2761377C2 (ru) 2017-04-03 2021-12-07 Ф. Хоффманн-Ля Рош Аг Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
AU2018247794A1 (en) 2017-04-05 2019-08-22 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to PD1 and LAG3
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5344755A (en) * 1990-04-21 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US5576423A (en) * 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders

Also Published As

Publication number Publication date
EP0813538A1 (de) 1997-12-29
US6414117B1 (en) 2002-07-02
US20030158399A1 (en) 2003-08-21
US6156887A (en) 2000-12-05
EP0813538A4 (de) 2001-10-31
EP1757621A2 (de) 2007-02-28
US5721351A (en) 1998-02-24
DE69636216T2 (de) 2007-04-19
AU718245B2 (en) 2000-04-13
JPH11501807A (ja) 1999-02-16
EP1757621A3 (de) 2008-02-13
AU5178396A (en) 1996-09-23
US6288218B1 (en) 2001-09-11
US6204371B1 (en) 2001-03-20
ES2264800T3 (es) 2007-01-16
ATE328891T1 (de) 2006-06-15
US6562343B1 (en) 2003-05-13
EP0813538B1 (de) 2006-06-07
US6066498A (en) 2000-05-23
CA2214589A1 (en) 1996-09-12
US6084083A (en) 2000-07-04
US7172750B2 (en) 2007-02-06
EP1757621B1 (de) 2011-09-07
US6066322A (en) 2000-05-23
WO1996027603A1 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
DE69636216D1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von immunstörungen
ATE289200T1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
ATE92523T1 (de) Verfahren zur abtrennung und reinigung von sialyl-transferasen.
ES2133329T3 (es) Variantes de il-3 humana.
DE3788313D1 (de) Renin-hemmende Di- und Tripeptide, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung.
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE175215T1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
WO2001042784A3 (en) Methods for screening compounds active on neurons
ATE203271T1 (de) Für die protein-kinase a-spezifische modifizierte oligonukleotide und verfahren zur deren verwendung
Montgomery et al. The influence of cognitive impairment on service use and caregiver response.
DK0966683T3 (da) Assays, midler, terapi og diagnose vedrørende moduleirng af cellulær DNA-reparationsaktivitet
AUPN674895A0 (en) Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
DE69929683D1 (de) Antisense modulierung von lfa-3
ATE312914T1 (de) Rdgb-proteine
Kishimoto et al. Polymorphism of submandibular-sublingual salivary proteins which promote adhesion of Streptococcus mutans serotype-c strains to hydroxyapatite
Scherz LATE ADOLESCENT AND EARLY ADULT MALE PERCEPTIONS OF THE FATHER-SON RELATIONSHIP: IMPLICATIONS FOR THE DEVELOPMENT OF SELF-ESTEEM.
Park Heritability of urine and plasma amylase activity
Dales et al. Conference Report: International Symposium on Multiple Sclerosis University of Western Ontario May 3-5, 1981
Harris et al. α-l-Fucosidase m cystic fibrosis: analysis of skin fibroblasts and liver
Schaal A STUDY ON THE INCREASE OF HEALTHY FAMILY FUNCTION THROUGH A TEACHING PROTOCOL USING SELECTED COMPONENTS OF BOWEN'S FAMILY SYSTEM THEORY AND SCHAEFER'S ORGANIZATIONAL CONTINGENCY MODEL.
Kiffer CLASSIFICATION OF DRINKING STYLES USING THE TOPOGRAPHICAL COMPONENTS OF BEER DRINKING.
ATE365747T1 (de) Proteindomänen der hepatischen untereinheit, die die aktivität auf glykogen lenkt, der proteinphosphatase 1, verfahren zu ihrer herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition